Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$48.7M
23M shares
52-week range
$1.82 – $12.80
3% from low
Exchange
NASDAQ
CS
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
www.bioharvest.comNo one on the platform currently holds BHST.
No tracked institution reports a position in BHST as of their last filing.
No one on the platform has traded BHST yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $43M | +23.7% | $-0.40 | $-0.40–$-0.38 | — | 3 |
| 2027 | $59M | +37.5% | $-0.16 | $-0.20–$-0.13 | — | 3 |
| 2028 | $96M | +63.1% | $0.41 | $0.38–$0.43 | 5.3× | 1 |
| 2029 | $129M | +34.6% | $0.83 | $0.78–$0.88 | 2.6× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $-0.13 | $-0.17 | -30.8% |
| 2026-05-14 | $-0.13 | $-0.11 | +15.4% |
| 2026-03-31 | $-0.10 | $-0.10 | +4.8% |
| 2025-11-13 | $-0.14 | $-0.14 | +0.0% |
| 2025-08-11 | $-0.11 | $-0.15 | -36.4% |
| 2025-05-15 | $-0.15 | $-0.13 | +13.3% |
| 2025-03-31 | $-0.12 | $-0.17 | -41.7% |
| 2024-11-25 | $-0.05 |
| $-0.16 |
| -220.0% |
| -0.77% |
| $228M |
| — |
| FFFutureFuel Corp. | $5.62 | -1.06% | $247M | — |
| FRDFriedman Industries, Incorporated | $45.63 | +3.21% | $329M | — |
Source: Financial Modeling Prep · peers by sector/industry
$BHST Live Webcast today @1pm ET from 46th Annual Canaccord Growth Conference. Watch CEO Zaki Rakib present following the August 11 2026 CDMO Manufacturing and Supply announcement and the sharing of Q2 2026 Financials. Webcast link: https://t.co/yLNTgZQQ87
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-10-bioharvest-sciences-inc-stock/ $BHST BioHarvest Sciences Earnings Transcript
View on StockTwits ↗$BHST News Release--> BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue and positions BioHarvest in sustainable rare luxury fragrance manufacturing . Read Full news release: https://bit.ly/45PSa3k
View on StockTwits ↗$BHST Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.17 up 29.17% YoY • Reported revenue of $8.84M up 3.78% YoY • BioHarvest Sciences Inc. expects the CDMO business to generate $4-$5 million in revenue, while consolidated EBITDA losses are expected to be in the range of $3 million to $5 million.
View on StockTwits ↗https://nfne.ws/309164 $BHST @BioHarvestBHSC #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResult
View on StockTwits ↗https://nfne.ws/309157 $BHST @BioHarvestBHSC #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Agreement #NASDAQ #Invest
View on StockTwits ↗$BHST News Release--> BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference. CEO Zaki Rakib will present at 1pm ET, August 12. Webcast link: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/nfY3m9akBmhvezmVQ8SM7d
View on StockTwits ↗https://nfne.ws/307087 $BHST @BioHarvestBHSC #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing
View on StockTwits ↗$BHST what the hell happen t6o this stock, is it going bankrupt
View on StockTwits ↗$BHST this will be one of those sleepers that makes a big move to $40 one day
View on StockTwits ↗$BHST BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026 https://marketwirenews.com/stock/bhst/news/bioharvest-sciences-to-report-second-quarter-2026-fi-6970270563276808.html?utm_source=stocktwits
View on StockTwits ↗https://nfne.ws/306896 $BHST @BioHarvestBHSC #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResult
View on StockTwits ↗https://nfne.ws/305238 $BHST @BioHarvestBHSC #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing
View on StockTwits ↗$BHST News Release--> BioHarvest Sciences to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC CEO Zaki Rakib will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on Wednesday, July 22, 2026, at 10:00 a.m. ET. In this virtual conference, Maxim Group Research Analysts sit down with leaders from companies at the forefront of innovation across beverages, food, supplements, and longevity. Participants will discuss shifting consumer preferences, the science behind emerging ingredients, building trusted brands, navigating regulation, and capturing share in some of the fastest-growing categories in consumer health. The event is limited to Maxim Digital members - to open an account, visit https://lnkd.in/eWYafewK View BioHarvest news release: https://ir.bioharvest.com/news/default.aspx
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.